Erythropoietic Protoporphyria clinical trials at UCSF
3 in progress, 1 open to eligible people
Longitudinal Study of the Porphyrias
open to all eligible people
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
San Francisco, California and other locations
HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP
Sorry, accepting new patients by invitation only
This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.
San Francisco, California and other locations
Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Sorry, in progress, not accepting new patients
To evaluate the long-term safety and tolerability of oral dersimelagon.
San Francisco, California and other locations
Our lead scientists for Erythropoietic Protoporphyria research studies include Bruce Wang, MD.